Disruption of RNA and protein trafficking in neurodegeneration

RNA-binding protein dynamics in ALS/FTD

Our laboratory focuses on the pathogenesis and treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), devastating neurodegenerative disorders with considerable genetic and pathologic overlap.  

Although the causes of ALS and FTD are diverse and only partially understood, approximatly 97% of ALS cases and 45% of FTD cases show nuclear clearance and cytoplasmic aggregation of the essential RNA-binding protein TDP-43.

The cause of TDP-43 mislocalization in disease remains unknown, but abundant evidence suggests that TDP-43 disruption is involved in the pathogenic cascade of disease. There is also growing genetic evidence for disruption of other RNA-binding proteins in ALS and FTD, highlighting a critical role for RNA-protein interactions in neuronal biology.

We are particularly interested in how nucleocytoplasmic transport and RNA processing intersect to regulate the localization and physiological functions of RNA-binding proteins.

Research

Mechanism and regulation of TDP-43 nucleocytoplasmic transport

Current studies in the lab focus on: (1) the mechanism of TDP-43 nuclear export; (2) the role of RNA in regulating TDP-43 localization; and (3) the development of RNA-based approaches to promote TDP-43 nuclear localization.

To that end, we utilize immortalized cell lines and primary neurons to monitor nucleocytoplasmic transport using automated high-content imaging and confocal microscopy. In addition, we apply biochemical, biophysical, and imaging methods, including RNAseq, proteomics, FRAP, and FRET, to analyze protein-protein and protein-RNA interactions.

In parallel, we are working to identify and test novel therapeutic strategies for promoting TDP-43 nuclear retention in patient-derived neurons, Drosophila, and mouse models.

Recent publications

Duan L, Zaepfel B, Aksenova V, Dasso M, Rothstein JD, Kalab P, Hayes LR. Nuclear RNA binding regulates TDP-43 nuclear localization and passive nuclear export. Cell Reports, 2022;40(3), 111106.

Hayes LR and Kalab P. Emerging therapies and novel targets for TDP-43 proteinopathy in ALS/FTD. Neurotherapeutics, 2022;19,1061-1084.

Team

Lindsey Hayes, MD, PhD

Principal Investigator

Associate Professor of Neurology

JHU School of Medicine, Brain Science Institute - Profile

Google Scholar

Petr Kalab, PhD

Co-Investigator

Research Associate Professor

JHU Whiting School of Engineering

Google Scholar

Xi Zhang, PhD

Research associate

Google Scholar

Tanuza Das, PhD

Postdoctoral fellow

Google Scholar

Xiuli Yang, MD, PhD

Research associate

Google Scholar

Students

- Tiffany Chao

Lab alumni

- Lauren Duan

- Kelly Bowen

Currently recruiting!

Now recruiting at all levels - technicians, graduate students, and postdoctoral fellows.

Interested candidates should send a CV to:

contact@hayeslab.science

 

Funding and collaboration